Xolremdi (mavorixafor) is a drug intended for the treatment of WHIM syndrome in patients older than 12 years[2][4]. It is the first oral drug in the class of CXCR4 receptor antagonists, which blocks the receptor and allows the release of white blood cells from the bone marrow into the bloodstream[2][3]. In a 52-week clinical trial, patients taking Xolremdi had an average 60% reduction in infections compared to placebo, with an average of 1.7 infections per year compared to 4.2 in the placebo group[3][6]. The drug also increased the amount of time neutrophil and lymphocyte counts in the blood were above safe limits—an average of 15 hours per day compared to 2.8 hours with placebo[5]. The most common side effects included low platelet count (21% of patients), rash, rhinitis and epistaxis[4]. The drug has not been shown to be effective in the treatment of warts that are part of WHIM syndrome[3][6].